Veeva is highly likely to be cited by AI engines for life-sciences enterprise software shortlists because it has strong third-party review presence (notably G2) and credible analyst/enterprise signals (Gartner Peer Insights). The biggest AI-citation risk is evaluation-stage “brand vs competitor” and “pricing” queries: Veeva’s first-party comparison and pricing surfaces appear thin/uncrawlable for AI, so models may rely on third parties instead of citing veeva.com.